Clinical trial
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
NCT00456092 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00456092 |
|---|---|
| Title | Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis |
| Official title | A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC-10004 in Subjects With Active Psoriatic Arthritis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriatic Arthritis |
| Intervention type | Drug |
| Interventions | Apremilast, Placebo |
| Enrollment | 204 |
| Start date | Mar 5, 2007 |
| Primary completion | May 9, 2009 |
| Completion | May 9, 2009 |
| First posted | Apr 4, 2007 |
| Last update posted | Jun 19, 2020 |
| Countries | Belgium, Canada, Germany, Netherlands, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: